A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack. International Headache Society (IHS) global practice recommendations for the Acute Treatment of Migraine suggest a second dose of the same medication within the recommended dose limit in people with headache relapse after successful initial treatment of a migraine attack. The primary purpose of this study is to evaluate the safety and tolerability of redosing of rimegepant when taken for the acute treatment of a migraine attack, as it is possible that some patients may benefit from a second dose of rimegepant in this setting.

NCT Number	NCT07609914
Lead Sponsor	Pfizer
Conditions	Acute Treatment of Migraine
Enrollment	400 participants
Start Date	2026-05-28
Primary Completion	2028-05-15 (estimated)
Study Completion	2028-05-15 (estimated)
Updated on ClinicalTrials.gov	2026-07-09